Dermata Therapeutics Inc., a late-stage biotechnology company, recently announced the results of its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial. The trial, focused on moderate-to-severe acne, met all three primary endpoints, demonstrating statistically significant results versus placebo at the study's conclusion. Results indicated that XYNGARI™ achieved significant separation from placebo after just four weeks of treatment, as well as at the 12-week primary endpoint required by the FDA. Following these positive results, Dermata has initiated additional manufacturing and is evaluating the next steps for the upcoming XYNGARI™ Phase 3 STAR-2 clinical trial, which will be followed by a 9-month extension study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.